MX2017002374A - Composiciones y metodos para tratar trastornos de la vision. - Google Patents

Composiciones y metodos para tratar trastornos de la vision.

Info

Publication number
MX2017002374A
MX2017002374A MX2017002374A MX2017002374A MX2017002374A MX 2017002374 A MX2017002374 A MX 2017002374A MX 2017002374 A MX2017002374 A MX 2017002374A MX 2017002374 A MX2017002374 A MX 2017002374A MX 2017002374 A MX2017002374 A MX 2017002374A
Authority
MX
Mexico
Prior art keywords
treat
vision disorders
compositions
methods
lanosterol
Prior art date
Application number
MX2017002374A
Other languages
English (en)
Inventor
Zhang Kang
Hou Rui
Cai Huimin
Original Assignee
Guangzhou Kangrui Biological Pharmaceutical Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Kangrui Biological Pharmaceutical Tech Co Ltd filed Critical Guangzhou Kangrui Biological Pharmaceutical Tech Co Ltd
Publication of MX2017002374A publication Critical patent/MX2017002374A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención proporciona esteroles y usos de los mismos para tratar trastornos de la visión. En una realización, se usa una composición que comprende una cantidad farmacéuticamente eficaz de lanosterol para tratar y/o prevenir trastornos de la visión en un sujeto. En otra realización, se usa una composición que comprende una cantidad farmacéuticamente eficaz de lanosterol para tratar las cataratas o la ceguera/visión alterada en un sujeto. En otra realización más, se usa una composición que comprende lanosterol para disolver fibrillas similares a amiloide de proteínas cristalinas.
MX2017002374A 2014-08-22 2015-08-24 Composiciones y metodos para tratar trastornos de la vision. MX2017002374A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462040721P 2014-08-22 2014-08-22
US201562194120P 2015-07-17 2015-07-17
PCT/US2015/046453 WO2016029199A1 (en) 2014-08-22 2015-08-24 Compositions and methods to treat vision disorders

Publications (1)

Publication Number Publication Date
MX2017002374A true MX2017002374A (es) 2017-09-15

Family

ID=55351326

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002374A MX2017002374A (es) 2014-08-22 2015-08-24 Composiciones y metodos para tratar trastornos de la vision.

Country Status (13)

Country Link
US (1) US10471076B2 (es)
EP (1) EP3182977B1 (es)
JP (1) JP6706020B2 (es)
KR (1) KR20170048426A (es)
CN (2) CN111529481B (es)
AU (1) AU2015305199A1 (es)
BR (1) BR112017003529A2 (es)
CA (1) CA2958868A1 (es)
EA (1) EA035798B1 (es)
HK (1) HK1243325A1 (es)
MX (1) MX2017002374A (es)
SG (1) SG11201701377YA (es)
WO (1) WO2016029199A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016029199A1 (en) 2014-08-22 2016-02-25 Kang Zhang Compositions and methods to treat vision disorders
CA2993196A1 (en) 2015-07-27 2017-02-02 Catacore, Inc Compositions for the treatment of cataracts
CN109481392B (zh) * 2015-09-02 2021-12-24 盛世泰科生物医药技术(苏州)有限公司 一种用于预防和治疗白内障的眼用制剂及其制备方法
CN107397745A (zh) * 2016-08-24 2017-11-28 上海毕傲图生物科技有限公司 唑类化合物眼用制剂
CN106344587A (zh) * 2016-08-24 2017-01-25 上海毕傲图生物科技有限公司 羊毛甾醇类化合物眼用制剂
EP3536698B1 (en) * 2017-01-25 2021-08-04 Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. Lanosterol prodrug compound and use thereof
GB2581656A (en) * 2017-11-17 2020-08-26 Piraee Mahmood Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders
CN109985052A (zh) * 2017-12-29 2019-07-09 上海蓝木化工有限公司 三萜类化合物的新用途
US11872236B2 (en) 2018-04-05 2024-01-16 Calasia Pharmaceuticals, Inc. Pharmacological agents for treating ocular diseases
BR112021001172A2 (pt) * 2018-07-25 2021-04-27 Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. forma cristalina do composto do pró-fármaco lanosterol e aplicação do mesmo
MX2021009520A (es) 2021-08-06 2023-02-07 Foodvica S A De C V Composicion oftalmica para el tratamiento de trastornos visuales.
CN115737654A (zh) 2021-09-03 2023-03-07 成都瑞沐生物医药科技有限公司 一种滴眼给药预防和/或治疗白内障的眼用制剂
CN116570706A (zh) * 2022-02-09 2023-08-11 上海瑞吉康生物医药有限公司 使用多肽治疗白内障的方法
WO2023198192A1 (zh) * 2022-04-15 2023-10-19 广州润尔眼科生物科技有限公司 甾体化合物在制备预防和/或治疗老花眼的药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9216106B2 (en) 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
WO2005084208A2 (en) * 2004-02-27 2005-09-15 New York University A novel class of sterol ligands and their uses in regulation of cholesterol and gene expression
US7517870B2 (en) * 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
US20100068251A1 (en) * 2006-10-10 2010-03-18 Jina Pharmaceuticals, Inc. Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof
EP2255788B1 (en) * 2008-02-29 2015-07-22 Nagoya Industrial Science Research Institute Liposome for delivery to posterior segment of eye and pharmaceutical composition for disease in posterior segment of eye
US9238036B2 (en) * 2008-08-05 2016-01-19 Amazonia Fitomedicamentos Ltda Pharmaceutical uses of lanosta-8,24-dien-3-ols
AU2013292644B2 (en) 2012-07-17 2018-04-19 Regents Of The University Of Michigan Inhibitors of alpha-crystallin aggregation for the treatment for cataract
CN104602670A (zh) * 2012-08-31 2015-05-06 博士伦公司 含有ω-3 脂肪酸的眼用组合物
WO2016029199A1 (en) 2014-08-22 2016-02-25 Kang Zhang Compositions and methods to treat vision disorders

Also Published As

Publication number Publication date
EA201790397A1 (ru) 2017-08-31
EP3182977A1 (en) 2017-06-28
BR112017003529A2 (pt) 2019-08-20
CN107206009A (zh) 2017-09-26
CN107206009B (zh) 2020-03-27
US20170065617A1 (en) 2017-03-09
CN111529481A (zh) 2020-08-14
HK1243325A1 (zh) 2018-07-13
CN111529481B (zh) 2023-09-15
EA035798B1 (ru) 2020-08-12
JP2017525769A (ja) 2017-09-07
AU2015305199A1 (en) 2017-04-13
EP3182977A4 (en) 2018-04-11
JP6706020B2 (ja) 2020-06-03
US10471076B2 (en) 2019-11-12
KR20170048426A (ko) 2017-05-08
EP3182977B1 (en) 2021-05-05
CA2958868A1 (en) 2016-02-25
SG11201701377YA (en) 2017-03-30
WO2016029199A1 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
MX2017002374A (es) Composiciones y metodos para tratar trastornos de la vision.
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2022000754A (es) Composiciones y metodos de uso de nintedanib para tratar enfermedades oculares con neovascularizacion anormal.
WO2018026722A8 (en) COMPOSITIONS AND METHODS FOR INHIBITING MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
MY186271A (en) Ophthalmic compositions and methods of use therefor
IL274234B (en) Preparations and methods for the treatment of eye diseases
PH12018502161A1 (en) Methods of treatment for cholestatic and fibrotic diseases
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
EP3713553A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF EYE DISEASES
MX2016016090A (es) Composicion oftalmica para el tratamiento de infeccion ocular.
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
EA201790893A1 (ru) Способы лечения офтальмологических расстройств
EP3618868A4 (en) METHODS AND COMPOSITIONS FOR TREATING ALLERGIC EYE DISEASES
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
SG11202012473UA (en) Ophthalmic compositions and methods for the treatment of eye disorders
PH12017501694A1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases
EA201800565A1 (ru) Композиция для лечения заболеваний уха, содержащая (+)-азасетрон
MX2018003799A (es) Nueva composicion oftalmica que contiene rebamipida y metodo para prepararla.
EA201700074A1 (ru) Стабильные не содержащие консерванты офтальмологические составы опиоидных антагонистов
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders
IL280952A (en) Methods and drug compounds for the treatment of ophthalmic diseases